M. Carini
Research Subjects
M. Carini has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
S. Serni
Aouc Careggi Firenze , Florence , ITALY
11 shared publicationsA. Cocci
Aouc Careggi Firenze , Florence , ITALY
5 shared publicationsM. Gacci
Aouc Careggi Firenze , Florence , ITALY
5 shared publicationsA Lapini
4 shared publicationsF. Sessa
4 shared publicationsA. Minervini
3 shared publications
Latest Publications
- 1 April 2017
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 14 (Supplement) , e189-e190
P-03-013 Malignant Priapism and Non Urologic Primitive Tumors are Related with the Poorer Prognosis in Men with Penile Metastases: Results of a Systematic Review
- 1 April 2017
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 14 (Supplement) , e189-e190
P-03-013 Malignant Priapism and Non Urologic Primitive Tumors are Related with the Poorer Prognosis in Men with Penile Metastases: Results of a Systematic Review
- 1 April 2017
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 14 (Supplement) , e190
P-03-014 Vitaros for the Treatment of Post Prostatectomy Erectile Dysfunction. An Effective Alternative?
- 1 April 2017
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 14 (Supplement) , e190
P-03-014 Vitaros for the Treatment of Post Prostatectomy Erectile Dysfunction. An Effective Alternative?
- 1 March 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (3) , e1370-e1371
Predictors of local recurrence after partial nephrectomy: Results from two-years follow up of a prospective multicentre study (RECORd 1 project)
- 1 March 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (3) , e1370-e1371
Predictors of local recurrence after partial nephrectomy: Results from two-years follow up of a prospective multicentre study (RECORd 1 project)
- 1 March 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (3) , e1817-e1818
Histopathological analysis of peritumoral pseudocapsule infiltration and surgical margin status after enucleative robot-assisted partial nephrectomy (RAPN) for malignant renal tumors
- 1 March 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (3) , e1817-e1818
Histopathological analysis of peritumoral pseudocapsule infiltration and surgical margin status after enucleative robot-assisted partial nephrectomy (RAPN) for malignant renal tumors
- 1 January 2017
- Published by Elsevier in The Journal of Sexual Medicine
- Vol. 14 (Supplement) , S82-S83
278 Sexual Lifestyle in Male and Females Medical Students: Results of an Italian Survey
- 1 January 2017
- Published by Elsevier in The Journal of Sexual Medicine
- Vol. 14 (Supplement) , S82-S83
278 Sexual Lifestyle in Male and Females Medical Students: Results of an Italian Survey
- 1 May 2016
- Published by Elsevier in The Journal of Sexual Medicine
- Vol. 13 (Supplement) , S217-S218
P-05-005 Sexual Desire and Orgasm of Male and Female Medical Students: Results of an Italian Survey
- 1 May 2016
- Published by Elsevier in The Journal of Sexual Medicine
- Vol. 13 (Supplement) , S217-S218
P-05-005 Sexual Desire and Orgasm of Male and Female Medical Students: Results of an Italian Survey
- 1 April 2015
- Published by Taylor & Francis in Cancer Investigation
- Vol. 33 (5) , 188-192
Cyberknife Treatment for Low and Intermediate Risk Prostate Cancer
Cyberknife is an emerging treatment for early stage prostate cancer. Between October 2012 and January 2014, 32 patients were treated in our institution. Prescribed dose was 35-36.25 Gy in five fractions. Biochemical response was observed in 22 patients. Four patients experienced G2 acute genitourinary toxicity and in two cases we recorded G3 acute GU toxicity. 5 patients experienced G2 acute proctitis. At last follow up visit, all patients were still alive. 29 remained free of disease at last follow up appointment, while three developed a biochemical recurrence. Our experience confirms the efficacy and safety of Cyberknife for localized prostate cancer.
- 1 April 2015
- Published by Taylor & Francis in Cancer Investigation
- Vol. 33 (5) , 188-192
Cyberknife Treatment for Low and Intermediate Risk Prostate Cancer
Cyberknife is an emerging treatment for early stage prostate cancer. Between October 2012 and January 2014, 32 patients were treated in our institution. Prescribed dose was 35-36.25 Gy in five fractions. Biochemical response was observed in 22 patients. Four patients experienced G2 acute genitourinary toxicity and in two cases we recorded G3 acute GU toxicity. 5 patients experienced G2 acute proctitis. At last follow up visit, all patients were still alive. 29 remained free of disease at last follow up appointment, while three developed a biochemical recurrence. Our experience confirms the efficacy and safety of Cyberknife for localized prostate cancer.
- Open Access
- 7 December 2003
- Published by Wiley in BJU International
- Vol. 92 (s3) , e15
Squamous cell carcinoma of the renal pelvis: nephrostomy tract tumour seeding
- 7 December 2003
- Published by Wiley in BJU International
- Vol. 92 (s3) , e15
Open AccessSquamous cell carcinoma of the renal pelvis: nephrostomy tract tumour seeding